ERBB2 and prostate cancer: Eighteen patients suffering from ErbB2-expressing metastatic breast cancers (13 patients), prostate cancers (two patients), head and neck cancer (one patient), non small cell lung cancer (one patient), or transitional cell carcinoma (one patient) (Table 1) were given at least five daily infusions of scFv(FRP5)-ETA, with total daily doses ranging from 100 μg to 1.4 mg.